Karine Tawagi MD (@DrKarineTawagi) ranks #9 among US gu cancer KOLs on X in 2026, by engagement from fellow physicians. 56 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: VOLGA, LITESPARK-011, TALAPRO-3. CMS Open Payments lists $41,223 in 2025 general payments.
At a Glance
- 20 posts naming a trial in 2026
- 16 trials discussed by name
- GU Cancer: US #9, Global #14 · 56 physicians engaged
- Leading physician voice: #1 of 6 physicians on CARE1; #2 of 5 physicians on BRCAAway
- CMS Open Payments lists $41,223 in 2025 general payments.
This Month
What Karine Tawagi MD has posted in the last 30 days. Updated November 10, 2026.
📣 another FDA approval in APMS ➡️ MANY in 2026 inc. pluvicto & capivasertib ➡️ now talazoparib/enza vs enza #TALAPRO3 for HRR-altered APMS (vs AMPLITUDE only BRCA2) ➡️ rPFS 77% vs 56% (HR 0.48) ⚠️ OS immature, G≥3 anemia 51%, 40% transfused; no docetaxel-triplet comparator https://t.co/Tt9qSqUacc
Gorgeous AM in Retiro Park ahead of exciting RCC updates #ESMO26: 🌟final KN564 @DrChoueiri 🌟PROs of RAMPART 🌟CA-IX PET 🌟cabo/atezo in metastatic papillary RCC @maughanonc 🌟EVP in RMC 🌟LACO-Stim CART 🌟KIM-1 @VincentWenxinXu 🌟PDL1 #CARE1 🌟LITESPARK011 QoL @DrDanielHeng https://t.co/uJj89STyi4
#CARE1 is a pragmatic biomarker-driven approach to help all of us decide how to pick btw 1L IO/IO & IO/TKI in metastic ccRCC ❓can PD-L1 expression help guide selection? ➡️ currently at 43% accrual & we anticipate results in coming years @AlbigesL #ESMO26 https://t.co/Z3eIlwgP15
💫#VOLGA: Durva + EV in cis-ineligible, like #EV303 but NO adjuvant EV here ⬆️ 2-year EFS (HR 0.51), OS (HR 0.58) & pCR (45% vs 10%) Triplet arm OS not significant & ⬆️ tox Less robust #s then EVP but how much benefit does adjuvant EV add? Can we use ctDNA/pCR to ⬇️? #ESMO26 https://t.co/UruMRqJPnI
🔥 full house before #ESMO26 Presidential: 🔹#INTerpath001: Intismeran autogene + pembro vs pembro in resected melanoma 🔹#VOLGA: Periop durva ± treme + EV in MIBC 🔹#DeLLphi-305: Tarlatamab + durva vs durva as 1L maintenance in ES-SCLC 🔹Daro + ADT + RT in very high-risk PCa https://t.co/16kmnFAZaU
Full house for Bladder/RCC updates first with #KN866 #ESMO26 Gem/cis in MIBC + placebo or pembro (➖) study & less relevance in the era of EVP SOC Vs similar trial NIAGARA was ➕ pCR 44.4% vs 35.8% EFS & OS not significant We wait #VOLGA tomorrow for more in this space https://t.co/uSLgxYSoMO
Who Amplifies Karine Tawagi MD
Physicians who reposted Karine Tawagi MD’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| GU Cancer | #9 | #14 | 56 | 107 | Full ranking |
Trials Karine Tawagi MD Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| VOLGA | 5 | #8 of 57 | Oct 24, 2026 |
| LITESPARK-011 | 4 | #5 of 37 | Oct 25, 2026 |
| TALAPRO-3 | 2 | #11 of 39 | Oct 26, 2026 |
| CARE1 | 2 | #1 of 6 | Oct 25, 2026 |
| NIAGARA | 2 | #10 of 32 | Oct 23, 2026 |
| LITESPARK-022 | 2 | #5 of 40 | Jun 15, 2026 |
| DeLLphi-305 | 1 | #50 of 86 | Oct 24, 2026 |
| CAPItello-281 | 1 | #9 of 21 | Oct 23, 2026 |
| TROPHY-U-01 | 1 | #7 of 10 | Oct 13, 2026 |
| PSMAddition | 1 | #3 of 13 | Jul 31, 2026 |
| EV-302 | 1 | #4 of 19 | May 1, 2026 |
| PROTEUS | 1 | #38 of 56 | May 1, 2026 |
| RETAIN1 | 1 | — | Feb 27, 2026 |
| BRCAAway | 1 | #2 of 5 | Feb 26, 2026 |
| PEACE-3 | 1 | #6 of 10 | Feb 26, 2026 |
| TALENT (TRIO-US B-12) | 1 | #19 of 23 | Feb 26, 2026 |
Karine Tawagi MD on VOLGA
💫#VOLGA: Durva + EV in cis-ineligible, like #EV303 but NO adjuvant EV here ⬆️ 2-year EFS (HR 0.51), OS (HR 0.58) & pCR (45% vs 10%) Triplet arm OS not significant & ⬆️ tox Less robust #s then EVP but how much benefit does adjuvant EV add? Can we use ctDNA/pCR to ⬇️? #ESMO26 https://t.co/UruMRqJPnI
🔥 full house before #ESMO26 Presidential: 🔹#INTerpath001: Intismeran autogene + pembro vs pembro in resected melanoma 🔹#VOLGA: Periop durva ± treme + EV in MIBC 🔹#DeLLphi-305: Tarlatamab + durva vs durva as 1L maintenance in ES-SCLC 🔹Daro + ADT + RT in very high-risk PCa https://t.co/16kmnFAZaU
Full house for Bladder/RCC updates first with #KN866 #ESMO26 Gem/cis in MIBC + placebo or pembro (➖) study & less relevance in the era of EVP SOC Vs similar trial NIAGARA was ➕ pCR 44.4% vs 35.8% EFS & OS not significant We wait #VOLGA tomorrow for more in this space https://t.co/uSLgxYSoMO
Karine Tawagi MD on LITESPARK-011
Gorgeous AM in Retiro Park ahead of exciting RCC updates #ESMO26: 🌟final KN564 @DrChoueiri 🌟PROs of RAMPART 🌟CA-IX PET 🌟cabo/atezo in metastatic papillary RCC @maughanonc 🌟EVP in RMC 🌟LACO-Stim CART 🌟KIM-1 @VincentWenxinXu 🌟PDL1 #CARE1 🌟LITESPARK011 QoL @DrDanielHeng https://t.co/uJj89STyi4
4) RCC: -LITESPARK012: pembro/lenva +/- belzutifan in 1L mRCC (➖PFS & OS press release) -LITESPARK011 final analysis + QoL belz/lenva vs cabo in 2L mRCC -Peri-op pembro + met-directed therapy in oligomet RCC -PD1/VEGF bispecific Inovescimab in RCC
Today 9/24/26 new approval in 2L clear cell mRCC with some caveats #LITESPARK011 💢 4mo PFS gain, higher ORR (53% vs 40%) & DOR (23 v 12mo) 💢 OS is not yet significant 💢 how does it perform post 1L IO/IO vs IO/TKI, weight of extra toxicity & optimal sequencing still unclear https://t.co/v4Q22JHxVa
Karine Tawagi MD on TALAPRO-3
📣 another FDA approval in APMS ➡️ MANY in 2026 inc. pluvicto & capivasertib ➡️ now talazoparib/enza vs enza #TALAPRO3 for HRR-altered APMS (vs AMPLITUDE only BRCA2) ➡️ rPFS 77% vs 56% (HR 0.48) ⚠️ OS immature, G≥3 anemia 51%, 40% transfused; no docetaxel-triplet comparator https://t.co/Tt9qSqUacc
3) Prostate CA: -#PROTEUS: perioperative apalutamide (plenary!) -mCSPC: identifying docetaxel benefit analyses from CHAARTED + ENZAMET, & ADT interruption #ADREAM, PARPi #TALAPRO3, #PSMAddition, ZZ-First -mCRPC: ADC to PSMA/STEAP1, #PLUDO doce vs Lu-617, AVPC chemo-IO
Karine Tawagi MD on CARE1
Gorgeous AM in Retiro Park ahead of exciting RCC updates #ESMO26: 🌟final KN564 @DrChoueiri 🌟PROs of RAMPART 🌟CA-IX PET 🌟cabo/atezo in metastatic papillary RCC @maughanonc 🌟EVP in RMC 🌟LACO-Stim CART 🌟KIM-1 @VincentWenxinXu 🌟PDL1 #CARE1 🌟LITESPARK011 QoL @DrDanielHeng https://t.co/uJj89STyi4
#CARE1 is a pragmatic biomarker-driven approach to help all of us decide how to pick btw 1L IO/IO & IO/TKI in metastic ccRCC ❓can PD-L1 expression help guide selection? ➡️ currently at 43% accrual & we anticipate results in coming years @AlbigesL #ESMO26 https://t.co/Z3eIlwgP15
Karine Tawagi MD on NIAGARA
Full house for Bladder/RCC updates first with #KN866 #ESMO26 Gem/cis in MIBC + placebo or pembro (➖) study & less relevance in the era of EVP SOC Vs similar trial NIAGARA was ➕ pCR 44.4% vs 35.8% EFS & OS not significant We wait #VOLGA tomorrow for more in this space https://t.co/uSLgxYSoMO
@TumorBoardTues @PGrivasMDPhD @IntegrityCE @tompowles1 @shilpaonc @montypal @cvulsteke @y_loriot @DrYukselUrun @MaxKates @Uromigos @drenriquegrande @AndreaNecchi @AmandaNizamMD @koshkin85 @apolo_andrea @MikeSerzanMD 3/26 #TumorBoardTuesday Cis-eligible MIBC: NIAGARA is prior SOC for perioperative tx in MIBC since 2024, after meeting EFS, OS, & pCR endpoints EVP now has significantly met EFS, OS, pCR 🤔BUT KN-B15 results @ ASCO GU➡️more FDA approved options available soon❓ @tompowles1 https://t.co/fApgI62jhV
Karine Tawagi MD on LITESPARK-022
📢 June 12 2026: the FDA approved adjuvant Belzutifan & Pembrolizumab for resected ccRCC based on #LITESPARK022 @katy_beckermann Monday Morning message is still impt here: 🌀 DFS gain vs toxicity 🤝 best fit: prioritize DFS delay & can tolerate anemia/hypoxia ⚠️ pending OS data https://t.co/H6gqfScfVN
Big morning for Belzutifan🎉#ASCOGU26 #LITESPARK011 combo w/ Lenva vs Cabo in 2L+ s/p IO in mRCC (55% prior TKI) ➕ PFS, ORR, immature OS, 20 pts w/ CR ⚠️15% hypoxia, 2/3 DR TKI, 1/3 DR Belz #LITESPARK022 adj belzu/pembro vs pembro x1yr ➕DFS, immature OS ⚠️ ~12% pts PRBC/ESA https://t.co/PcEOhfXdtc
Karine Tawagi MD on DeLLphi-305
🔥 full house before #ESMO26 Presidential: 🔹#INTerpath001: Intismeran autogene + pembro vs pembro in resected melanoma 🔹#VOLGA: Periop durva ± treme + EV in MIBC 🔹#DeLLphi-305: Tarlatamab + durva vs durva as 1L maintenance in ES-SCLC 🔹Daro + ADT + RT in very high-risk PCa https://t.co/16kmnFAZaU
Karine Tawagi MD on CAPItello-281
Lovely walking tour & sunset in Madrid @myESMO #ESMO26 Looking forward today to: #VOLGA peri-op durva/treme/EV MIBC & Daro in very high risk PCa both in presidential session🌟 #KNB15 ctDNA analysis Claudin-6 ADC in GCT #CAPITELLO281 capi OS in mCSPC NAT ICI in penile CA https://t.co/p31vBubCOj
Karine Tawagi MD’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Groundbreaking KN-B15 for EVP in cis-eligible MIBC 👤 most T3/T4a, 90% pure urothelial 🎖️ EFS HR 0.53, OS HR 0.65, pCR 55.8% vs 32.5% ⚠️¾ grade 3 TEAE, 25% stopped NA EVP & 28.6% adj EVP d/t TEAE ‼️36% neuropathy, 63% skin, 23% 👁️ ❓how many got IO in control arm https://t.co/yBE2uQrfKp
RC48G00 @tompowles1 in 2L+ mUC s/p chemo 1L, no prior EV 🌀this trial inc HER2 low, DV = ADC w/ MMAE payload, n=151 ➡️Coh A HER-2 3+ or 2+ +FISH ➡️Coh B HER-2 2+ w/ -FISH or 1+ ✅ORR >62%, CR>16% ❓How does this fit w/ 1L EVP? ➡️Phase 3 DV + P ongoing but chemo/IO control https://t.co/UsG1U9LLb3
Another GU FDA approval June 12, 2026: Capivasertib + Abi/Pred in mCSPC, based on ➕rPFS (HR 0.81) ⚠️ OS immature ⚠️ cost/toxicity: diarrhea, ⬆️BG, rash ❓How does it compare to triplet w/ docetaxel ❓biomarker refinement: IHC cutoff 90% vs NGS PTEN-loss VS p-AKT ❓duration https://t.co/sDZZMSXGco
Exploratory ctDNA analysis from #KNB15 #ESMO26 🧬 ctDNA status is strongly prognostic: ctDNA-negative status (baseline/postsurgery) ass w/ improved EFS & pCR 💊 Presurgery ctDNA clearance was higher with EVP vs GC 📈 Periop EVP achieved favorable EFS regardless of ctDNA status https://t.co/5i26zRIYL0
& great discussion @MichvdHeijden https://t.co/M1RCy8ttiW
Industry Payments
CMS Open Payments · 2025 general payments
$41,223 across 32 payments